Moderna's Cancer Vaccine Worked. The Stock Still Got Crushed.
Moderna (MRNA) spent months turning a cancer-vaccine headline into a moonshot stock. Thursday the full Phase 3 numbers hit the tape early, and the stock got cut roughly in half of a good year in one session.
Shares sank as much as about 25% and closed with a high-teens percent loss. Roughly $24 billion in market value vanished after data for the personal melanoma vaccine with Merck (MRK) leaked ahead of a big cancer meeting in Madrid.
The combo of Moderna's mRNA shot and Merck's Keytruda cut the risk of cancer coming back or death by 42% versus Keytruda alone. Risk of the cancer spreading far from the first site, or death, fell about 38%. After two years, about 82% of patients on the combo were still free of recurrence versus about 70% on Keytruda alone.
Those are real clinical numbers. They are also not the dream numbers the stock had already priced after August's teaser.
Sell the News, or Miss the Bar?
In August the companies said the late-stage trial showed a meaningful cut in recurrence without dumping the hazard ratios. Moderna stock exploded from there and stayed one of the year's best S&P names into this week.
Thursday's detail showed a hazard ratio near 0.58 for recurrence or death. An earlier mid-stage study had pointed to a bigger relative benefit. Analysts called the late-stage result solid and strong on the stats, then quickly argued about whether it was enough to justify how far the stock had already run.
UBS framed it as a classic sell-the-news event after a months-long surge. BMO said investors wanted a cleaner read-through to other tumors and left disappointed. Merck shares only slipped about 1% to 2%. Moderna took the full momentum unwind.
What the Trial Actually Is
The shot is built from mutations unique to each patient's tumor. It is not a one-size vial sitting on a pharmacy shelf. That is the promise and the manufacturing headache. Moderna has talked about a path toward a U.S. filing and a possible 2027 launch window if regulators play ball.
First late-stage evidence that a personalized mRNA vaccine plus a checkpoint inhibitor can keep high-risk melanoma quieter after surgery is still a scientific milestone. Markets do not pay for milestones the same way labs do. Markets pay for how far the result clears the story already sold.
How to Read the Stock From Here
Even after the crash, Moderna is still massively higher than where it sat before the August headline. That means a lot of the easy narrative money already left. What remains is slower work: filing strategy, manufacturing scale, pricing, and whether other tumor types ever match melanoma.
Leak chaos made it worse. Oncology Central published embargoed detail early. The companies pushed the data out. Trading halted at points. None of that changes the hazard ratio. It does change how fast momentum funds exit.
Personalized Shots Are Hard Businesses
A shot built on each patient's tumor changes sounds like science fiction until you sit with the logistics. Tissue has to move. Gene reading has to finish. Factories have to turn a custom design into doses on a clock that cancer clinics will not bend. That complexity is why the product can excite doctors and still be hard to model like a normal pill business.
Merck brings Keytruda reach and cancer-clinic relationships. Moderna brings the mRNA design engine that made the COVID era famous. Together they can run a landmark melanoma program. Investors still have to decide how much of Moderna's stock value should rest on one tough skin-cancer setting versus a wider pipeline that has let people down before.
The leak made the education process violent. Instead of a controlled Saturday symposium narrative, the market got a midday scramble. Solid hazard ratios arrived inside a momentum unwind. That combination is why good data and a bad tape can live in the same headline without contradiction.
Bottom line: The vaccine worked in a way oncology trials respect. The stock had already celebrated a bigger party than Thursday's data could host.
Money Morning is not a registered investment advisor. This article is for informational purposes only and should not be construed as investment advice. Past performance is not indicative of future results. We may receive compensation for promoting third-party products and services. Always do your own due diligence before investing.